IKIgor Kiss

Igor Kiss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Igor Kiss has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychophysiological changes during breast cancer treatment: a longitudinal analysis of subjective and objective indicators

    by Iva Burešová, Petr Květon, Martin Jelínek, Jana Halámková, Igor Kiss, Iva Hrnčiříková, KateřIna Kapounková

    Advances in early detection and treatment of breast cancer have led to improved survival rates, shifting attention toward the physical and psychological consequences of treatment. Adjuvant therapies are frequently associated with fatigue, reduced quality of life, sleep disturbances, and psychological distress, yet longitudinal data capturing changes in both subjective and objective health indicators during treatment remain limited. The present study aimed to examine changes in selected psychophysiological characteristics in breast cancer patients from diagnosis through completion of adjuvant treatment. A longitudinal design with two assessment points was employed: before treatment initiation and after completion of adjuvant therapy. The sample consisted of 75 women with breast cancer (mean age = 52.04; sd = 11.63). Self-report measures assessed fatigue (MFI), quality of life (EORTC QLQ-C30), anxiety and depression (HADS), sleep quality (PSQI), and motivation for physical activity (MPAM-R). Objective indicators included body mass index (BMI) and functional exercise capacity measured by the six-minute walk test (6MWT). Changes over time were analyzed using General Linear Models for repeated measures, with age and treatment duration included as covariates. Holm-Bonferroni correction was applied to control for multiple testing. Following treatment, patients exhibited significant increases in physical and general fatigue and a marked deterioration in the physical component of quality of life. BMI increased modestly but significantly over time. In contrast, no significant change was observed in objectively measured physical fitness (6MWT). Depressive symptoms significantly decreased after treatment, suggesting psychological adaptation despite physical deterioration. Age-related effects indicated greater post-treatment worsening of sleep quality in younger women, whereas older women showed a more pronounced decline in physical quality of life. The findings reveal a notable discrepancy between subjective health perceptions and objective physical capacity during breast cancer treatment. They underscore the importance of routine monitoring of fatigue, quality of life, and body weight, and support the implementation of individualized, age-sensitive supportive care strategies. Addressing psychophysiological burden during treatment may improve long-term well-being and clinical outcomes in breast cancer survivors.


  • Open Access

    Editorial: Women in gastrointestinal cancers, volume II: 2022

    by Nadia M. Hamdy, Lisardo Bosca, Sukh Mahendra Singh, Srinivasa Reddy Bonam, Igor Kiss, Divya P. Kumar, Aditi Banerjee

    Editorial: Women in gastrointestinal cancers, volume II: 2022

  • Open Access

    Impact of Cancer and 12 Weeks of Chemotherapy on the Balance of the Autonomic Nervous System in Cancer Patients

    by Pavlina Bazalova, Kateřina Kapounková, Igor Kiss

    Cancer and its treatment itself (especially chemotherapy) is associated with number of negative effects on the human body. These include mainly cardiac toxicity, peripheral neuropathy, bone loss, depression, anxiety, nausea, pain, cognitive changes, fatigue, fitness reduction and more. Fatigue is one of the most common negative effects, often persists long after treatment and is described as insurmountable and is associated with lower parasympathetic activity. The autonomic nervous system (ANS) is the main homeostatic regulatory system of the body, it regulates involuntary physiological processes. We believe that this part of the peripheral nervous system can be negatively affected by cancer and chemotherapy, which can have a negative impact on all the processes that control this system. Most drugs used in oncology lead to chemotherapy-induced peripheral neuropathy and are expected to have an influence on the autonomic nervous system. Activity and balance of the autonomic nervous system depend on a range of dynamically changing and quantitatively different conditions such as age, stress, physical activity, sleep, illness, fatigue and more. Methods: To evaluate ANS activity, spectral analysis of heart rate variability (HRV) was assessed. During treatment, 19 oncological patients with prescribed adjuvant chemotherapy measured HRV 3 times a week using a chest strap with a HRV monitor mySASY and mySASY software. Parasympathetic activity (PA), sympathetic activity (S), total score (TS) and total power (TP) were selected as indicators of ANS activity. The patients were women aged 50.38 ± 10,29 with BMI 25,72 ± 4,16. The mean values for the first 14 days of treatment and then for 14 days after 12 weeks of treatment were compared. Data normality was verified by Kolmogorov-Smirnov test (K-S) and static significance was calculated by t-test. All statistical tests were performed at a significance level of 5%. Results: There was a significant decrease in values for three parameters. The PA decreased from 3,80 ± 1,56 to 3,14 ± 1,67 (p = .03), TP decreased from 3,65 ± 1,87 to 2,82 ± 2,08 (p = .04), TS decreased from 3,40 ± 1,67 to 2,67 ± 1,73 (p = .01). Sympathetic activity was somewhat but not significantly higher, increased from 6,74 ± 1,22 to 6,80 ± 1,44 (p = .83). Conclusion: During the 12 weeks of treatment with adjuvant chemotherapy, there was a significant reduction in parasympathetic activity, total score, and total power. A decrease in PA is usually associated with lower regenerative abilities of the organism, a decrease in TP is associated with a decrease in the activity of the entire ANS. TS evaluates the total power and balance of both ANS branches. The higher the values, the more the body is regenerated and ready for further stress and response to stress.

  • Open Access

    Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

    by T. Buchler, R. Chloupkova, A. Poprach, O. Fiala, I. Kiss, K. Kopeckova, L. Dusek, L. Slavicek, M. Kohoutek, J. Finek, et al.

    Background: Although bevacizumab and monoclonal antibodies directed against epidermal growth factor receptor (EGFR) cetuximab and panitumumab are commonly used in the treatment of metastatic colorectal cancer (mCRC) without activating RAS mutations, the optimal sequencing of these agents is currently unclear.


  • Comparison of efficacy and toxicity of bevacizumab in combination with chemotherapy in the first, second, and third or higher line of treatment for metastatic colorectal carcinoma (mCRC): Data from the Czech multi-institutional registry.

    by Igor Kiss, Zbynek Bortlicek, Bohuslav Melichar, Alexandr Poprach, Jana Halamkova, Rostislav Vyzula, Ladislav Dusek, Tomas Buchler

    E14622 Background: Data from the Czech national registry of patients treated with targeted therapies for mCRC were analyzed retrospectively to compare treatment outcomes for bevacizumab in combination with chemotherapy in the 1st, 2nd and 3rd line of treatment. Methods: The database was launched in 2005 as a clinical registry of patients with mCRC treated with bevacizumab. Epidemiological and clinical data are entered by all Czech comprehensive cancer centers administering targeted therapy. In total, 4487 mCRC patients who received bevacizumab combined with chemotherapy in either 1st line (n=3990, 88.9%), 2nd line (n=386, 8.6%), or 3rd and higher line (n=111, 2.5%) had evaluable data and were included in the present analysis. Survival was calculated using the Kaplan-Meier method, and the differences were assessed using the log-rank test. Results: Statistically significant differences were observed in the efficacy of combination chemotherapy with bevacizumab between the treatment lines. The objective response rate (ORR) in the 1st, 2nd, and 3rd/higher line was 42.9%, 34.0% and 8.3%; (p<0.001) respectively. Similarly, in the 1st, 2nd, and 3rd/higher line median progression free survival (mPFS) was 11.3 months (95% CI 11.0-11.7 months), 9.5 months (95% CI 8.2-10.9 months) , and 7.3 months (95% CI 5.9-8.7 months; p<0.001), and median overall survival (mOS) was 28.4 months (95% CI 27.1-29.8 months), 25.9 months (95% CI 19.4-32.4 months), and 15.0 months (95% CI 10.7-19.3 months; p<0.001), respectively. The spectrum of the most common adverse events was comparable in the 1st, 2nd, or 3rd/higher line, and incidence of adverse events was similar at 11.6%, 8.8% and 8.1%, respectively. Conclusions: The efficacy of bevacizumab in combination with chemotherapy decreased when administered in later lines of treatment for mCRC while the incidence and spectrum of toxicities remains unchanged.